Metformin HCL en es it fr

Metformin HCL Brand names, Metformin HCL Analogs

Metformin HCL Brand Names Mixture

  • No information avaliable

Metformin HCL Chemical_Formula


Metformin HCL RX_link

Metformin HCL fda sheet

Metformin_HCL FDA

Metformin HCL msds (material safety sheet)

Metformin_HCL MSDS

Metformin HCL Synthesis Reference

No information avaliable

Metformin HCL Molecular Weight

211.215 g/mol

Metformin HCL Melting Point

300 oC

Metformin HCL H2O Solubility

1000 mg/L

Metformin HCL State


Metformin HCL LogP


Metformin HCL Dosage Forms

Liquid for injection; Tablets for oral use (125 mg, 250 mg, or 500 mg)

Metformin HCL Indication

For use in the treatment of hypertension.

Metformin HCL Pharmacology

Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the L-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.

Metformin HCL Absorption

Absorption from the gastrointestinal tract is variable but averages approximately 50%.

Metformin HCL side effects and Toxicity

The oral LD50 of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. Symptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.

Metformin HCL Patient Information

No information avaliable

Metformin HCL Organisms Affected

Humans and other mammals